New cancer drug copycat faces off against erbitux in major trial
NCT ID NCT07543471
First seen Apr 26, 2026 · Last updated May 13, 2026 · Updated 3 times
Summary
This early-stage study tests whether a new drug called HLX05-N works as well as the standard drug Erbitux for people with metastatic colorectal cancer that has certain genetic features. About 387 adults will receive either HLX05-N or Erbitux along with chemotherapy. The goal is to compare how the drugs move through the body, their safety, and whether the body fights them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.